Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A | P37088 | 16/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6013451 | 0.87 | SCNN1A (0.51) | SCNN1A | |
| SCHEMBL916915 | 0.86 | SCNN1A (0.46) | SCNN1A | |
| Hydrochloric Acid SCHEMBL6013453 | 0.86 | SCNN1A (0.46) | SCNN1A | |
| SCHEMBL6013447 | 0.84 | SCNN1A (0.49) | SCNN1A | |
| SCHEMBL6013439 | 0.83 | SCNN1A (0.50) | SCNN1A | |
| Hydrochloric Acid SCHEMBL6013446 | 0.83 | SCNN1A (0.49) | SCNN1A | |
| SCHEMBL4146570 | 0.83 | SCNN1A (0.51) | SCNN1A | |
| SCHEMBL6013452 | 0.82 | SCNN1A (0.48) | SCNN1A | |
| SCHEMBL15092694 | 0.81 | SCNN1A (0.47) | SCNN1A | |
| Hydrochloric Acid SCHEMBL5673038 | 0.81 | SCNN1A (0.50) | SCNN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663235-A4 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1663235-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1656096-A2 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS | Parion Sciences, Inc. (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | JOHNSON MICHAEL R (US) | 2005-04-28 | — | — | US | disclosed |
| WO-2005034847-A2 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS | PARION SCIENCES, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005018644-A1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050009727-A1 | Laundry and cleaning compositions | THE PROCTER & GAMBLE COMPANY (US) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | KCNN3, KCNN1, KCNN2 | SCNN1A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.